Sakar Healthcare Jumps 2.6% as It Secures 3rd and 4th Oncology Injection Approvals in Europe
By Shishta Dutta | Published at: Jul 16, 2025 03:31 PM IST
Ahmedabad, July 16, 2025 – Sakar Healthcare Ltd (NSE: SAKAR) rose 2.68% to ₹360 as of 2:57 PM IST on Wednesday. The stock gained after the company announced it had secured its third and fourth Marketing Authorisations (MAs) for oncology injections in Europe, further strengthening its regulatory presence in the region.
Stock Snapshot
Sakar Healthcare shares are trading at ₹360, which is a 2.68% gain on July 16, 2025, at 3:00 PM IST. Sakar Healthcare shares have gained 7.90% over the last year, up 16.36% year-to-date, and 12.91% in the previous month.
| Metric | Value |
|---|---|
| Last Traded Price | ₹360 (as of 2:57 PM IST) |
| Change (%) | +₹9.40 (+2.6%) |
| Day’s Range | ₹344.50 – ₹366.00 |
| VWAP | ₹360.72 |
| 52-Week High | ₹380.80 (19-Jun-2025) |
| 52-Week Low | ₹210.10 (28-Mar-2025) |
| Market Cap | ₹801.17 crore |
| Free Float Market Cap | ₹371.89 crore |
| Adjusted P/E | 43.84 |
| Series | BE (ESM-1) |
Key Update: Two New MAs from Bulgaria and Bosnia
According to an exchange filing, Sakar Healthcare has received two additional MAs for oncology injections, Carboplatin and Docetaxel, from Bulgaria and Bosnia, respectively.
These approvals come under the European Union’s stringent dossier guidelines and add to the two earlier MAs secured by the company. The existing products cover treatments for breast, prostate, lung, and colorectal cancers, while Carboplatin extends the scope to ovarian and other solid tumors.
Strategic Outlook
Sakar confirmed that it is preparing for commercial supply based on its earlier two approvals and aims to expand exports across European markets. The company expects more MAs in the coming months as part of its ongoing filings across the EU and rest-of-world markets.
“These approvals now widen the scope to export anti-cancer injections to the European countries,” the company stated. “These MAs will speed up the export of multiple oncology products to the EU region manufactured at Sakar’s vertically integrated oncology product manufacturing site.”
About Sakar Healthcare
Listed on the NSE since April 11, 2019, Sakar Healthcare Ltd is a Gujarat-based pharmaceutical firm focused on manufacturing oncology formulations. It operates an EU-GMP-approved API-integrated facility and is actively expanding its international regulatory portfolio, especially in the oncology segment.
This development marks a significant regulatory milestone for Sakar and is seen as a key enabler for future revenue growth through European market penetration.
REF: https://nsearchives.nseindia.com/corporate/SAKAR_16072025110047_Announcement.pdf
Disclaimer: At HDFC SKY, we take utmost care and due diligence in curating and presenting news and market-related content. However, inadvertent errors or omissions may occasionally occur.
If you have any concerns, questions, or wish to point out any discrepancies in our content, please feel free to write to us at content@hdfcsec.com.
Please note that the information shared is intended solely for informational purposes and does not make any investment recommendations
